share_log
Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>

StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)

kopsource ·  11/28/2022 15:12

StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a research note published on Friday morning. The firm issued a sell rating on the medical technology company's stock.

Several other brokerages have also commented on BIOL. Maxim Group decreased their price objective on shares of BIOLASE from $10.00 to $5.00 in a report on Friday, November 11th. Benchmark decreased their price objective on shares of BIOLASE to $7.00 in a report on Wednesday, November 16th. Finally, Ascendiant Capital Markets decreased their price objective on shares of BIOLASE to $14.00 in a report on Wednesday, November 16th.

Get BIOLASE alerts:

BIOLASE Stock Up 4.6 %

Shares of NASDAQ BIOL opened at $1.02 on Friday. The company has a current ratio of 2.46, a quick ratio of 1.27 and a debt-to-equity ratio of 0.92. BIOLASE has a 12 month low of $0.93 and a 12 month high of $13.83. The firm has a market capitalization of $7.25 million, a PE ratio of -0.28 and a beta of 1.45. The firm has a fifty day simple moving average of $2.01 and a two-hundred day simple moving average of $3.51.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Commonwealth Equity Services LLC increased its stake in shares of BIOLASE by 117.8% in the 1st quarter. Commonwealth Equity Services LLC now owns 101,046 shares of the medical technology company's stock worth $35,000 after acquiring an additional 54,650 shares in the last quarter. Capital Wealth Alliance LLC purchased a new stake in BIOLASE during the 2nd quarter valued at about $51,000. Citadel Advisors LLC purchased a new stake in BIOLASE during the 2nd quarter valued at about $118,000. State Street Corp grew its position in BIOLASE by 4.5% during the 1st quarter. State Street Corp now owns 436,076 shares of the medical technology company's stock valued at $154,000 after purchasing an additional 18,682 shares during the last quarter. Finally, Essex Investment Management Co. LLC grew its position in BIOLASE by 62.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 105,318 shares of the medical technology company's stock valued at $256,000 after purchasing an additional 40,440 shares during the last quarter. 21.21% of the stock is currently owned by institutional investors.

BIOLASE Company Profile

(Get Rating)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.

Further Reading

  • Get a free copy of the StockNews.com research report on BIOLASE (BIOL)
  • Best Buy Proves Brick and Mortar is Here to Stay
  • MarketBeat: Week in Review 11/21 – 11/25
  • Microsoft Shares: Is it Time to Back Up the Truck?
  • Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
  • Institutional Support for Analog Devices Remains High

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.